Corporate | 19 May 2022 07:30

Spexis to present at H.C. Wainwright Global Investment Conference

Spexis AG / Key word(s): Conference
Spexis to present at H.C. Wainwright Global Investment Conference
19.05.2022 / 07:30

Allschwil, Switzerland, May 19, 2022

Spexis to present at H.C. Wainwright Global Investment Conference

Spexis AG (SIX: SPEX) today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, in Miami Beach, FL, USA and virtually. Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The in-person presentation will be on Tuesday, May 24 ^th at 3 PM EDT. Conference details will be available on the Spexis website in the Investor Relations section here .

For further information please contact:

For Investors:

Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
IR@spexisbio.com

Raimund Gabriel
MC Services
spexis@mc-services.eu
Ph: +49 89 210 228 0 For Media:

Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch


Dr. Brigitte Keller/Laurie Doyle
MC Services
spexis@mc-services.eu
Europe: +49 89 210 228 0
U.S.: +1 339 832 0752

About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor AG and EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For further information please visit: www.spexisbio.com .

Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

End of Media Release

Language:	English
Company:	Spexis AG
	Hegenheimermattweg 125
	4123 Allschwil
	Switzerland
Phone:	+41 61 567 1600
Fax:	+41 61 567 1601
E-mail:	info@spexisbio.com
Internet:	www.spexisbio.com
ISIN:	CH0106213793
Valor:	SPEX
Listed:	SIX Swiss Exchange
EQS News ID:	1356137

End of News EQS News Service